Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (TCRT) reports developments as an early-stage biotechnology company focused on orally administered small-molecule therapeutics for obesity and related metabolic disorders. Recent updates center on ALN1003, a non-hormonal, non-incretin oral candidate evaluated in preclinical diet-induced obesity models, including body-weight, liver and metabolic biomarker findings.
Company news also reflects Alaunos's transition from earlier TCR-T cell therapy programs for solid tumors, including the TCR-T Library trial, the Sleeping Beauty cell engineering platform and the hunTR discovery platform. Recurring corporate updates include operating results, research spending, capital-structure actions, Nasdaq listing compliance and governance changes.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) announced that CEO Kevin S. Boyle Sr. and VP of Research & Development Drew Deniger will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 9:20am ET. The presentation will be available via a live webcast on the company’s website, with an archived replay accessible for 30 days. Alaunos focuses on oncology cell therapies, developing T-cell receptor therapies using its proprietary Sleeping Beauty gene transfer technology and targeting major tumor-related mutations.